September 27, 2022
The Federal Circuit imposed a temporary stay Tuesday that blocks Pfizer from launching a generic version of the coronary artery test Lexiscan, even though a Delaware federal judge ruled earlier this year that the new drug wouldn't actually infringe any patents Gilead has on Lexiscan.
May 20, 2022
Gilead lost its bid to shield its Lexiscan brand of cardiac stress agent from generic competition by Pfizer when the top federal judge in Delaware ruled the new drug wouldn't actually infringe any of Gilead's patents.
January 20, 2022
Federal Circuit judges will consider next week whether a medical device startup's founder can attack a patent he helped develop after a U.S. Supreme Court decision in the dispute last year narrowed rules for blocking inventors from challenging their own patents.